Bridging treatment prior to chimeric antigen receptor T‐cell therapy in multiple myeloma
British Journal of Haematology · 2024
DOI: 10.1111/bjh.19227 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift British Journal of Haematology, 2024. Verfasst von Susan Bal und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology/Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Multiple Myeloma. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 34 Literaturangaben.
Abstract (Originalsprache)
Autologous patient‐derived adoptive T‐cell therapies have revolutionized the management of relapsed multiple myeloma (MM). However, the current manufacturing and quality control processes result in lengthy vein‐to‐vein time, making bridging therapy necessary for most patients. Yet the decision and choice of optimal bridging therapy are complex in the heavily pretreated relapsed MM patient. In this perspective piece, the authors provide their approach and considerations while selecting an optimal bridging regimen before autologous chimeric antigen receptor T‐cell therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology/Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
ORCID-Profile: Susan Bal, Luciano J Costa
Zitieren
APA
Bal, S., & Costa, L. J. (2024). Bridging treatment prior to chimeric antigen receptor T‐cell therapy in multiple myeloma. British Journal of Haematology. https://doi.org/10.1111/bjh.19227
Vancouver
Bal S, Costa LJ. Bridging treatment prior to chimeric antigen receptor T‐cell therapy in multiple myeloma. British Journal of Haematology. 2024. doi:10.1111/bjh.19227
BibTeX
@article{Bal2024,
author = {Bal, Susan and Costa, Luciano J},
title = {Bridging treatment prior to chimeric antigen receptor T‐cell therapy in multiple myeloma},
journal = {British Journal of Haematology},
year = {2024},
doi = {10.1111/bjh.19227}
}
EUVIMED